Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Blackrock Inc (BLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Blackrock Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $225 (market cap $29.97B), while Blackrock Inc trades at $1,165.05 (market cap $179.79B). The key difference: Blackrock Inc is far larger — about 6× Alnylam Pharmaceuticals, Inc.'s market cap, and Blackrock Inc pays a 1.97% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BLK | |
|---|---|---|
Market Cap | $29.97B | $179.79B |
Sector | Health | Financials |
52-Week High | $491.22 | $1.20K |
52-Week Low | $205.48 | $922.90 |
Enterprise Value | $27.93B | $180.89B |
Volume | — | 641,547 |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
BLK trades at $1,159.09, up 2.45% today, with strong technical and fundamental momentum. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to $24.22 billion in 2025, though net income margin dipped to 22.93%. Recent news highlights BlackRock's involvement in a $500 billion AI financing initiative with Nvidia and other Wall Street firms, signaling strategic positioning in emerging technology investments.
Outlook remains positive with analyst consensus at Buy (78.79%) and a $1,350 price target, though overbought RSI levels and legal scrutiny over mutual fund practices present near-term risks. The company's expansion into tokenized money market products and sustained dividend payments support long-term growth, but investors should monitor margin pressures and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →
